|
1
|
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
|
J Clin Oncol
|
2010
|
14.79
|
|
2
|
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
|
N Engl J Med
|
2015
|
5.03
|
|
3
|
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas.
|
Neuro Oncol
|
2008
|
4.39
|
|
4
|
Inequality in early childhood: risk and protective factors for early child development.
|
Lancet
|
2011
|
3.48
|
|
5
|
Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis.
|
Neuro Oncol
|
2004
|
3.25
|
|
6
|
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
|
J Clin Oncol
|
2007
|
3.07
|
|
7
|
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.
|
J Clin Oncol
|
2008
|
2.92
|
|
8
|
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
|
J Clin Oncol
|
2008
|
2.71
|
|
9
|
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
|
Cancer Discov
|
2012
|
2.61
|
|
10
|
Effects of early childhood psychosocial stimulation and nutritional supplementation on cognition and education in growth-stunted Jamaican children: prospective cohort study.
|
Lancet
|
2005
|
2.55
|
|
11
|
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article.
|
J Neurosurg
|
2010
|
2.42
|
|
12
|
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group.
|
Neurosurgery
|
2012
|
2.19
|
|
13
|
End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.
|
J Clin Oncol
|
2009
|
2.13
|
|
14
|
The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.
|
Neurosurgery
|
2015
|
2.06
|
|
15
|
Consensus on the role of human cytomegalovirus in glioblastoma.
|
Neuro Oncol
|
2012
|
2.02
|
|
16
|
Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
|
J Clin Oncol
|
2007
|
2.01
|
|
17
|
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.
|
J Clin Oncol
|
2011
|
1.92
|
|
18
|
Development of a robust method for generating 7.0 T multichannel phase images of the brain with application to normal volunteers and patients with neurological diseases.
|
Neuroimage
|
2007
|
1.88
|
|
19
|
Early childhood stimulation benefits adult competence and reduces violent behavior.
|
Pediatrics
|
2011
|
1.86
|
|
20
|
Seizure characteristics and control following resection in 332 patients with low-grade gliomas.
|
J Neurosurg
|
2008
|
1.79
|
|
21
|
A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.
|
Nat Genet
|
2012
|
1.73
|
|
22
|
The effect of psychosocial stimulation on cognition and behaviour at 6 years in a cohort of term, low-birthweight Jamaican children.
|
Dev Med Child Neurol
|
2010
|
1.69
|
|
23
|
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.
|
J Neurosurg
|
2008
|
1.66
|
|
24
|
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
|
Neuro Oncol
|
2009
|
1.66
|
|
25
|
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
|
J Neurosurg
|
2010
|
1.65
|
|
26
|
Prognostic significance of intracranial dissemination of glioblastoma multiforme in adults.
|
J Neurosurg
|
2005
|
1.63
|
|
27
|
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?
|
Neuro Oncol
|
2011
|
1.50
|
|
28
|
Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity.
|
AJNR Am J Neuroradiol
|
2005
|
1.48
|
|
29
|
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).
|
Neuro Oncol
|
2010
|
1.46
|
|
30
|
Early childhood stunting is associated with poor psychological functioning in late adolescence and effects are reduced by psychosocial stimulation.
|
J Nutr
|
2007
|
1.43
|
|
31
|
A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.43
|
|
32
|
Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM.
|
J Neurooncol
|
2008
|
1.42
|
|
33
|
Clinical trial end points for high-grade glioma: the evolving landscape.
|
Neuro Oncol
|
2011
|
1.42
|
|
34
|
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging.
|
Neuro Oncol
|
2012
|
1.38
|
|
35
|
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
|
Neuro Oncol
|
2009
|
1.38
|
|
36
|
A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).
|
J Neurooncol
|
2008
|
1.37
|
|
37
|
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.
|
Neuro Oncol
|
2004
|
1.33
|
|
38
|
Diagnosis and treatment of recurrent high-grade astrocytoma.
|
J Clin Oncol
|
2006
|
1.32
|
|
39
|
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.
|
Neuro Oncol
|
2011
|
1.31
|
|
40
|
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
|
Neuro Oncol
|
2009
|
1.30
|
|
41
|
DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.
|
Neuro Oncol
|
2011
|
1.29
|
|
42
|
Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.
|
J Neurosurg
|
2006
|
1.28
|
|
43
|
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
|
Neuro Oncol
|
2012
|
1.27
|
|
44
|
Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.
|
Neurosurgery
|
2007
|
1.27
|
|
45
|
Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury.
|
J Neurosurg
|
2005
|
1.25
|
|
46
|
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
|
J Clin Oncol
|
2006
|
1.25
|
|
47
|
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.
|
Neuro Oncol
|
2013
|
1.25
|
|
48
|
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
|
Neuro Oncol
|
2009
|
1.22
|
|
49
|
Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo.
|
AJNR Am J Neuroradiol
|
2005
|
1.22
|
|
50
|
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
|
J Neurooncol
|
2009
|
1.21
|
|
51
|
GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with brain tumor at 7 T.
|
Magn Reson Imaging
|
2008
|
1.20
|
|
52
|
Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.
|
Neuro Oncol
|
2013
|
1.20
|
|
53
|
Dynamic susceptibility contrast perfusion imaging of radiation effects in normal-appearing brain tissue: changes in the first-pass and recirculation phases.
|
J Magn Reson Imaging
|
2005
|
1.20
|
|
54
|
Effects of psychosocial stimulation and dietary supplementation in early childhood on psychosocial functioning in late adolescence: follow-up of randomised controlled trial.
|
BMJ
|
2006
|
1.18
|
|
55
|
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.
|
J Neurooncol
|
2008
|
1.18
|
|
56
|
Inherited variation in immune genes and pathways and glioblastoma risk.
|
Carcinogenesis
|
2010
|
1.17
|
|
57
|
Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.17
|
|
58
|
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.
|
Neuro Oncol
|
2009
|
1.17
|
|
59
|
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
|
Clin Cancer Res
|
2012
|
1.15
|
|
60
|
Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.
|
Neurosurgery
|
2012
|
1.13
|
|
61
|
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
|
Clin Cancer Res
|
2007
|
1.13
|
|
62
|
Current chemotherapy for glioblastoma.
|
Cancer J
|
2003
|
1.12
|
|
63
|
Multiinstitutional validation of the University of California at San Francisco Low-Grade Glioma Prognostic Scoring System. Clinical article.
|
J Neurosurg
|
2009
|
1.12
|
|
64
|
Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.
|
Neuro Oncol
|
2013
|
1.11
|
|
65
|
Comparison of T(1) and T(2) metabolite relaxation times in glioma and normal brain at 3T.
|
J Magn Reson Imaging
|
2008
|
1.10
|
|
66
|
Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
|
J Neurosurg
|
2005
|
1.10
|
|
67
|
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
|
J Neurooncol
|
2009
|
1.10
|
|
68
|
Quality of life in adults with brain tumors: current knowledge and future directions.
|
Neuro Oncol
|
2008
|
1.09
|
|
69
|
Brain metastases.
|
Curr Probl Surg
|
2004
|
1.07
|
|
70
|
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
|
Neuro Oncol
|
2014
|
1.06
|
|
71
|
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy.
|
J Neurosurg
|
2004
|
1.06
|
|
72
|
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
|
Neuro Oncol
|
2010
|
1.05
|
|
73
|
Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival.
|
J Neurooncol
|
2009
|
1.05
|
|
74
|
Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging.
|
Neuro Oncol
|
2013
|
1.04
|
|
75
|
Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group.
|
Lancet Oncol
|
2013
|
1.03
|
|
76
|
Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group.
|
Lancet Oncol
|
2013
|
1.03
|
|
77
|
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
|
Neuro Oncol
|
2014
|
1.02
|
|
78
|
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme.
|
J Neurooncol
|
2006
|
1.02
|
|
79
|
Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma.
|
J Neurosurg
|
2004
|
1.02
|
|
80
|
Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme.
|
Neuro Oncol
|
2010
|
1.00
|
|
81
|
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
|
Neuro Oncol
|
2004
|
0.99
|
|
82
|
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
|
Neuro Oncol
|
2010
|
0.99
|
|
83
|
7-Tesla susceptibility-weighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.99
|
|
84
|
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study.
|
J Clin Oncol
|
2004
|
0.98
|
|
85
|
Apparent diffusion coefficient and fractional anisotropy of newly diagnosed grade II gliomas.
|
NMR Biomed
|
2009
|
0.98
|
|
86
|
Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme.
|
Neuro Oncol
|
2004
|
0.97
|
|
87
|
Impact of bevacizumab chemotherapy on craniotomy wound healing.
|
J Neurosurg
|
2010
|
0.96
|
|
88
|
Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial.
|
J Neurooncol
|
2003
|
0.96
|
|
89
|
Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.
|
Neuro Oncol
|
2010
|
0.95
|
|
90
|
Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma.
|
J Magn Reson Imaging
|
2011
|
0.95
|
|
91
|
Quality of life in low-grade glioma patients receiving temozolomide.
|
Neuro Oncol
|
2008
|
0.95
|
|
92
|
Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
|
J Neurosurg
|
2010
|
0.95
|
|
93
|
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
|
Neuro Oncol
|
2009
|
0.94
|
|
94
|
Feasibility of dynamic susceptibility contrast perfusion MR imaging at 3T using a standard quadrature head coil and eight-channel phased-array coil with and without SENSE reconstruction.
|
J Magn Reson Imaging
|
2006
|
0.94
|
|
95
|
O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas.
|
Neuro Oncol
|
2004
|
0.94
|
|
96
|
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
|
Clin Cancer Res
|
2012
|
0.94
|
|
97
|
Conditional probability of survival in patients with newly diagnosed glioblastoma.
|
J Clin Oncol
|
2011
|
0.93
|
|
98
|
Unaliasing lipid contamination for MR spectroscopic imaging of gliomas at 3T using sensitivity encoding (SENSE).
|
Magn Reson Med
|
2006
|
0.92
|
|
99
|
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
|
Neurosurg Focus
|
2006
|
0.91
|
|
100
|
Multiparametric characterization of grade 2 glioma subtypes using magnetic resonance spectroscopic, perfusion, and diffusion imaging.
|
Transl Oncol
|
2009
|
0.91
|
|
101
|
Susceptibility-weighted MR imaging of radiation therapy-induced cerebral microbleeds in patients with glioma: a comparison between 3T and 7T.
|
Neuroradiology
|
2013
|
0.91
|
|
102
|
Characterization of metabolites in infiltrating gliomas using ex vivo ¹H high-resolution magic angle spinning spectroscopy.
|
NMR Biomed
|
2014
|
0.90
|
|
103
|
Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors.
|
Neurosurgery
|
2002
|
0.90
|
|
104
|
Neuroimaging: diagnosis and response assessment in glioblastoma.
|
Cancer J
|
2012
|
0.90
|
|
105
|
Psychosocial intervention improves the development of term low-birth-weight infants.
|
J Nutr
|
2004
|
0.90
|
|
106
|
Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.
|
Acta Neuropathol
|
2015
|
0.90
|
|
107
|
Three-dimensional J-resolved H-1 magnetic resonance spectroscopic imaging of volunteers and patients with brain tumors at 3T.
|
Magn Reson Med
|
2007
|
0.89
|
|
108
|
Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.
|
J Neurooncol
|
2010
|
0.89
|
|
109
|
Secondary gliosarcoma: a review of clinical features and pathological diagnosis.
|
J Neurosurg
|
2010
|
0.87
|
|
110
|
3D sensitivity encoded ellipsoidal MR spectroscopic imaging of gliomas at 3T.
|
Magn Reson Imaging
|
2009
|
0.87
|
|
111
|
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
|
Neuro Oncol
|
2011
|
0.87
|
|
112
|
Central neurocytoma: a review.
|
J Neurooncol
|
2004
|
0.87
|
|
113
|
Repeated operations for infiltrative low-grade gliomas without intervening therapy.
|
J Neurosurg
|
2003
|
0.86
|
|
114
|
Endpoints for clinical trials and revised assessment in neuro-oncology.
|
Curr Opin Neurol
|
2012
|
0.86
|
|
115
|
Computer-aided detection of radiation-induced cerebral microbleeds on susceptibility-weighted MR images.
|
Neuroimage Clin
|
2013
|
0.86
|
|
116
|
Identifying malignant transformations in recurrent low grade gliomas using high resolution magic angle spinning spectroscopy.
|
Artif Intell Med
|
2012
|
0.85
|
|
117
|
The role of PCV chemotherapy in the treatment of central neurocytoma: illustration of a case and review of the literature.
|
Surg Neurol
|
2003
|
0.85
|
|
118
|
A critical evaluation of cystic features in primary glioblastoma as a prognostic factor for survival.
|
J Neurosurg
|
2011
|
0.85
|
|
119
|
Relationship between choline and apparent diffusion coefficient in patients with gliomas.
|
J Magn Reson Imaging
|
2008
|
0.84
|
|
120
|
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
|
Curr Oncol Rep
|
2011
|
0.83
|
|
121
|
MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas.
|
Neuro Oncol
|
2011
|
0.83
|
|
122
|
Small molecule and monoclonal antibody therapies in neurooncology.
|
Cancer Control
|
2005
|
0.82
|
|
123
|
Partial-volume model for determining white matter and gray matter cerebral blood volume for analysis of gliomas.
|
J Magn Reson Imaging
|
2006
|
0.82
|
|
124
|
Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study.
|
Clin Cancer Res
|
2007
|
0.81
|
|
125
|
Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM.
|
J Magn Reson Imaging
|
2012
|
0.81
|
|
126
|
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
|
J Neurooncol
|
2014
|
0.80
|
|
127
|
Glial tumors: the current state of scientific knowledge.
|
Clin Neurosurg
|
2006
|
0.80
|
|
128
|
Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme.
|
J Neurooncol
|
2007
|
0.80
|
|
129
|
Recent medical management of glioblastoma.
|
Adv Exp Med Biol
|
2012
|
0.80
|
|
130
|
Improving resection of malignant glioma.
|
Lancet Oncol
|
2006
|
0.80
|
|
131
|
SSBP2 variants are associated with survival in glioblastoma patients.
|
Clin Cancer Res
|
2012
|
0.79
|
|
132
|
Medical therapy of gliomas.
|
J Neurooncol
|
2014
|
0.79
|
|
133
|
Short-echo three-dimensional H-1 MR spectroscopic imaging of patients with glioma at 7 Tesla for characterization of differences in metabolite levels.
|
J Magn Reson Imaging
|
2014
|
0.79
|
|
134
|
Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.
|
Neurosurgery
|
2015
|
0.79
|
|
135
|
Automated prescription of oblique brain 3D magnetic resonance spectroscopic imaging.
|
Magn Reson Med
|
2012
|
0.78
|
|
136
|
Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.78
|
|
137
|
A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.
|
Neuro Oncol
|
2002
|
0.78
|
|
138
|
Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.
|
Neuro Oncol
|
2013
|
0.78
|
|
139
|
Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.
|
J Neurooncol
|
2016
|
0.78
|
|
140
|
Clinical trials in brain tumor surgery.
|
Neuroimaging Clin N Am
|
2010
|
0.78
|
|
141
|
Spatial characteristics of newly diagnosed grade 3 glioma assessed by magnetic resonance metabolic and diffusion tensor imaging.
|
Transl Oncol
|
2012
|
0.78
|
|
142
|
Intraventricular neurocytomas.
|
Neurosurg Clin N Am
|
2003
|
0.77
|
|
143
|
It is time to include patients with brain tumors in phase I trials in oncology.
|
J Clin Oncol
|
2011
|
0.77
|
|
144
|
11C-CHO PET in optimization of target volume delineation and treatment regimens in postoperative radiotherapy for brain gliomas.
|
Nucl Med Biol
|
2011
|
0.77
|
|
145
|
General and neurological complications of targeted therapy.
|
Handb Clin Neurol
|
2012
|
0.76
|
|
146
|
Editor's note.
|
Neuro Oncol
|
2012
|
0.76
|
|
147
|
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.76
|
|
148
|
Association of growth in utero with cognitive function at age 6-8 years.
|
Early Hum Dev
|
2006
|
0.75
|
|
149
|
Treatment for posterior fossa dissemination of primary supratentorial glioma.
|
J Neurosurg
|
2007
|
0.75
|
|
150
|
Laser Ablation vs Open Resection for Deep-Seated Tumors: The Case for Open Resection.
|
Neurosurgery
|
2016
|
0.75
|
|
151
|
Current perspectives on neuro-oncology.
|
Neurotherapeutics
|
2009
|
0.75
|
|
152
|
Multidisciplinary care of patients with brain tumors.
|
Surg Oncol Clin N Am
|
2013
|
0.75
|